RxDoctor Payments DataLook up a doctor →

le Hua, MD

Neurology · Las Vegas, NVNPI 1215197892

Payments from drug & device makers

$5,541,788in general payments, 2019–2025

Across 635 payments — averaging $8727.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2.1M
  • Genentech, Inc.$1.2M
  • AbbVie$613K
  • Biogen$564K
  • EMD Serono, Inc.$246K
  • TG Therapeutics, Inc.$217K
  • plus $638K from 16 others
$42,044in research payments, 2019–2025

Across 38 payments — averaging $1106.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$36K
  • F. Hoffmann-la Roche AG$4K
  • EMD Serono, Inc.$1K

What the payments were for

  • Consulting fees$217,17456%
  • Speaking & faculty fees$115,75530%
  • Travel & lodging$39,89510%
  • Food & beverage$11,4683%
  • Education$2180%
  • Gifts$9110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,541,788 in reported general payments places this provider in the 95th percentile of 145 neurology providers in Nevada.

See all neurology providers in Nevada

Medicare billing

Part B allowed, 2024
$85,654
Medicare patients
145
Services billed
8,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EnspryngSatralizumab-Mwge15$254,446
Kesimpta PenOfatumumab28$234,381
TysabriNatalizumab18$160,759
AubagioTeriflunomide16$149,837
MayzentSiponimod11$107,582
CopaxoneGlatiramer Acetate11$60,359
Glatiramer Acetate18$35,752
Dalfampridine ErDalfampridine99$26,161
Teriflunomide17$4,065
Carbamazepine ErCarbamazepine11$3,533
Gabapentin102$2,407
Baclofen60$1,082
Modafinil23$1,041
Duloxetine Hcl36$720
Pregabalin32$673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech USA, Inc.Enspryng$45,649$254,44615 claims
BiogenTysabri$563,920$160,75918 claims
SanofiAubagio$164,153$149,83716 claims
NovartisMayzent$2,076,571$107,58211 claims
Teva Pharmaceuticals USA, Inc.Copaxone$70$60,35911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 145 neurology providers in Nevada.

Other neurology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →